NCT02996890已完成1 期
Double Blinded, Randomized, Placebo Controlled, Dose Finding Trial to Evaluate the Optimal Dose of MV-ZIKA, a New Vaccine Against Zika Virus, in Regard to Immunogenicity, Safety, and Tolerability in Healthy Volunteers
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 48
- 试验地点
- 4
- 主要终点
- Immunogenicity: Functional anti-Zika antibodies as measured by PRNT
研究概览
简要总结
Double blinded, randomized, placebo-controlled, dose finding, multi-center, phase 1 trial in 48 healthy volunteer subjects.
After completion of screening procedures, the subjects are randomized to one of four treatment groups (different dosage strengths and placebo) All subjects will receive study treatment at day 0 and will return on day 28. Subjects randomized to treatment groups with two vaccinations will receive a second treatment at day 28.
Subjects will return on day 56 for the final visit.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •healthy volunteers aged 18 to 55
- •subjects of child bearing potential must perform reliable method of contraception
排除标准
- •immune deficiency, history of HIV, HBV, HCV
- •drug addiction
- •vaccination within 4 weeks prior to study or planned vaccination during study
- •prior receipt of any Zika vaccine
- •recent infection 1 week prior to screening
- •relevant medical history interfering with aim of study
- •neoplastic disease, hematological malignancy
- •history of autoimmune disease
- •psychological condition that affects ability to participate in the study
- •history of severe adverse reactions to vaccine administration
- •history of anaphylaxis
- •allergic reactions, abnormal lab values, or concomitant medication per decision of the investigator
- •use of immunosuppressive drugs within 30 days before screening or planned use during study
- •receipt of blood products within 120 days before screening or planned use during study
- •pregnancy, unreliable contraception method
- •decision of the investigator
- •regular blood plasma donor
结局指标
主要结局
Immunogenicity: Functional anti-Zika antibodies as measured by PRNT
时间窗: 56 days
Functional anti-Zika antibodies as measured by PRNT.
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
Safety and Tolerability of NTX-101 in Korean Healthy VolunteersHealthy VolunteersNCT05041543Pinotbio, Inc.36
已完成
1 期
TAK-648 Multiple-Rising Dose Study in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT02430870Takeda48
招募中
1 期
A Phase I Study of DDN-A-0101 in Healthy Volunteers and Elder PeopleAlzheimer DiseaseNCT06367426Pharmacobio100
已完成
1 期
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Deuremidevir Hydrobromide for SuspensionRespiratory Syncytial Virus InfectionsNCT06328400Vigonvita Life Sciences24
撤回
1 期
Phase I Dose Escalation SARS-CoV Recombinant S Protein, With and Without Adjuvant, Vaccine StudySARSNCT01376765National Institute of Allergy and Infectious Diseases (NIAID)